drugsTreatmentPhase 2

Mavrostobart

aka Mavrostobart (PT199)

Mavrostobart is an experimental monoclonal antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at CD73 / adenosine axis.

Mavrostobart (PT199) is a monoclonal antibody developed by Phanes Therapeutics. Its target is CD73 / adenosine axis. ClinicalTrials.gov describes the intervention as: Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT05431270, plans to enrol 40 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How it works, step by step · animated schematic, not to scale; chosen from the modality "monoclonal antibody"

Monoclonal antibodies →

Modality

monoclonal antibody

Mechanism

Monoclonal antibody directed at CD73 / adenosine axis, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

Brand / code

PT199

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

Mavrostobart

intervention: Mavrostobart

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.